Cargando…
CRF-R1 Antagonist Treatment Exacerbates Circadian Corticosterone Secretion under Chronic Stress, but Preserves HPA Feedback Sensitivity
Despite promising initial reports, corticotropin-releasing factor receptor type-1 (CRF-R1) antagonists have mostly failed to display efficacy in clinical trials for anxiety or depression. Rather than broad-spectrum antidepressant/anxiolytic-like drugs, they may represent an ‘antistress’ solution for...
Autores principales: | Ibarguen-Vargas, Yadira, Leman, Samuel, Palme, Rupert, Belzung, Catherine, Surget, Alexandre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707167/ https://www.ncbi.nlm.nih.gov/pubmed/34959395 http://dx.doi.org/10.3390/pharmaceutics13122114 |
Ejemplares similares
-
An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes
por: Futch, Hunter S., et al.
Publicado: (2019) -
Antidepressants recruit new neurons to improve stress response regulation
por: Surget, A, et al.
Publicado: (2011) -
Modulation of corticosterone and changes of signal molecules in the HPA axis after cold water swimming stress
por: Feng, Jing Hui, et al.
Publicado: (2021) -
Adult hippocampal neurogenesis shapes adaptation and improves stress response: a mechanistic and integrative perspective
por: Surget, A., et al.
Publicado: (2021) -
CRF Receptor Antagonist Astressin-B Reverses and Prevents Alopecia in CRF Over-Expressing Mice
por: Wang, Lixin, et al.
Publicado: (2011)